Literature DB >> 11266414

The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients.

G M Joynt1, J Lipman, C D Gomersall, R J Young, E L Wong, T Gin.   

Abstract

The aim of this study was to determine the pharmacokinetic profile of the normal recommended dose of ceftriaxone in critically ill patients and to establish whether the current daily dosing recommendation maintains plasma concentrations adequate for antibacterial efficacy. Ceftriaxone at a recommended dose of 2 g iv was administered od to 12 critically ill patients with severe sepsis and normal serum creatinine concentrations. Blood samples were taken at pre-determined intervals over the first 24 h and on day 3 for measurement of ceftriaxone concentrations. There was wide variability in drug disposition, explained by the presence of variable renal function and identified by the measurement of creatinine clearance. In nine patients with normal renal function, there was a high level of creatinine clearance (mean +/- S.D., 41 +/- 12 mL/min) and volume of distribution (20 +/- 3.3 L), which resulted in an elimination half-life of 6.4 +/- 1.1 h. In comparison with normal subjects, ceftriaxone clearance was increased 100%, volume of distribution increased 90% and the elimination half-life was similar. Three patients had substantially suboptimal plasma ceftriaxone concentrations. We confirm previous findings that ceftriaxone clearance in critically ill patients correlates with renal clearance by glomerular filtration. The elimination half-life is prolonged (21.4 +/- 9.8 h) in critically ill patients with renal failure when compared with previously published data in non-critically ill patients with renal failure. We conclude that in critically ill patients with normal renal function, inadequate plasma concentrations may result following od bolus dosing of ceftriaxone. Drug accumulation may occur in critically ill patients with renal failure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11266414     DOI: 10.1093/jac/47.4.421

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  46 in total

1.  Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.

Authors:  Rainer Gattringer; Eleonora Urbauer; Friederike Traunmüller; Markus Zeitlinger; Pejman Dehghanyar; Petra Zeleny; Wolfgang Graninger; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

2.  Increase of microcirculatory blood flow enhances penetration of ciprofloxacin into soft tissue.

Authors:  Christian Joukhadar; Pejman Dehghanyar; Friederike Traunmüller; Robert Sauermann; Bernhard Mayer-Helm; Apostolos Georgopoulos; Markus Müller
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  Population pharmacokinetics of ceftriaxone and pharmacodynamic considerations in haemodialysed patients.

Authors:  Nicolas Simon; Bertrand Dussol; Emmanuelle Sampol; Raj Purgus; Philippe Brunet; Bruno Lacarelle; Yvon Berland; Bernard Bruguerolle; Saïk Urien
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 4.  Clinical implications of antibiotic pharmacokinetic principles in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2013-09-18       Impact factor: 17.440

Review 5.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 6.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

7.  High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery.

Authors:  Nicolas Nesseler; Marie-Clémence Verdier; Yoann Launey; Alexandre Malherbe; Marine Dermu; Caroline Piau; Erwan Flécher; Olivier Tribut; Yannick Mallédant; Philippe Seguin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

8.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

9.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

10.  The clinical relevance of plasma protein binding changes.

Authors:  Jason A Roberts; Federico Pea; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.